Impfung gegen Tumorwachstum zurErprobung in Berlin an der Charite und in Göttingen:Aastrom Biosciences (Nasdaq: ASTM), in Ann Arbor, Michigan, has produced kits that enable hospitals to create antitumor vaccines from the patient's own dendritic cells, a component of blood. Aastrom CEO and president Doug Armstrong says early trials of the vaccine show 30 to 40 percent remission rates in patients whose renal cancer or melanoma had resisted conventional treatment.ANN ARBOR, Mich., April 24 /PRNewswire Interactive News Release/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM - news) announced today financial results for the quarter and nine months ended March 31, 2001. For the quarter, the Company reported a net loss of $1.7 million, or $.05 per common share, an improvement from a net loss of $2.4 million, or $.09 per common share in 2000. For the nine months ended March 31, 2001, the Company reported a net loss of $4.0 million, or $.12 per common share, compared to $8.0 million, or $.40 per common share in 2000.
``During the third quarter, we aggressively moved ahead with plans to complete our DC-I dendritic cell product and initiate European marketing during 2001,'' stated R. Douglas Armstrong, Ph.D., President and Chief Executive Officer of Aastrom. ``Beta site testing of our DC-I product began during the quarter, and we have now expanded into two of the nation's leading cancer research and treatment centers: the Barbara Ann Karmanos Cancer Institute (Detroit, MI) and Beth Israel Deaconess Medical Center (Boston, MA). We have also recently entered into evaluation agreements with two leading German cancer centers. The initiation of external evaluations at these premier cancer institutions increases Aastrom's momentum to deliver during this calendar year, a quality dendritic cell product to research and clinical sites that are developing cancer treatments with dendritic cell-based vaccines.''
ANN ARBOR, Mich., April 19 /PRNewswire/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM - news) announced today that it has entered into agreements with the Universitatsklinikum Charite, Berlin, Germany, and the University of Gottingen, Gottingen, Germany to begin European evaluation of its DC-I dendritic cell product for use in cancer vaccines
Gestern +35% nach Artikel im Redherring,heute wohl 8%minus,überkauft?
www.redherring.com/...=story&doc_id=890019289&channel=10000001
Sehr interessant auch der Artikel und die Seite von Layton BioScience: Cell regeneration gets real
www.redherring.com/...=story&channel=70000007&doc_id=300019030
Companies in this nascent sector tell of a day when injected brain cells can be used to grow millions of new ones and repair damage from stroke or spinal cord injuries. But Layton BioScience's lead scientists actually did it with 12 stroke victims. Was this a fluke? If anybody can prove that it wasn't, it's this group. Phase IIa clinical trials are under way.
MARKET Setting its sights on what will someday become multibillion-dollar markets for cell therapies to treat central nervous system disorders, typically resulting from spinal cord injuries or brain damage from stroke; the latter afflicts 600,000 Americans each year, killing about 160,000 and permanently disabling the rest.
In March 1999, doctors at the University of Pittsburgh drilled a hole in Sylvia Elam's head and injected 6 million neuron-like cells into the basal ganglia of her brain. At lunch the next day she could taste her food for the first time since suffering a stroke six years earlier. Within three months, she regained feeling in her right side, got over a bad stammer, and learned to walk almost normally.
"I am fully convinced that the improvements came from that operation," says Ms. Elam, now 67
``During the third quarter, we aggressively moved ahead with plans to complete our DC-I dendritic cell product and initiate European marketing during 2001,'' stated R. Douglas Armstrong, Ph.D., President and Chief Executive Officer of Aastrom. ``Beta site testing of our DC-I product began during the quarter, and we have now expanded into two of the nation's leading cancer research and treatment centers: the Barbara Ann Karmanos Cancer Institute (Detroit, MI) and Beth Israel Deaconess Medical Center (Boston, MA). We have also recently entered into evaluation agreements with two leading German cancer centers. The initiation of external evaluations at these premier cancer institutions increases Aastrom's momentum to deliver during this calendar year, a quality dendritic cell product to research and clinical sites that are developing cancer treatments with dendritic cell-based vaccines.''
ANN ARBOR, Mich., April 19 /PRNewswire/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM - news) announced today that it has entered into agreements with the Universitatsklinikum Charite, Berlin, Germany, and the University of Gottingen, Gottingen, Germany to begin European evaluation of its DC-I dendritic cell product for use in cancer vaccines
Gestern +35% nach Artikel im Redherring,heute wohl 8%minus,überkauft?
www.redherring.com/...=story&doc_id=890019289&channel=10000001
Sehr interessant auch der Artikel und die Seite von Layton BioScience: Cell regeneration gets real
www.redherring.com/...=story&channel=70000007&doc_id=300019030
Companies in this nascent sector tell of a day when injected brain cells can be used to grow millions of new ones and repair damage from stroke or spinal cord injuries. But Layton BioScience's lead scientists actually did it with 12 stroke victims. Was this a fluke? If anybody can prove that it wasn't, it's this group. Phase IIa clinical trials are under way.
MARKET Setting its sights on what will someday become multibillion-dollar markets for cell therapies to treat central nervous system disorders, typically resulting from spinal cord injuries or brain damage from stroke; the latter afflicts 600,000 Americans each year, killing about 160,000 and permanently disabling the rest.
In March 1999, doctors at the University of Pittsburgh drilled a hole in Sylvia Elam's head and injected 6 million neuron-like cells into the basal ganglia of her brain. At lunch the next day she could taste her food for the first time since suffering a stroke six years earlier. Within three months, she regained feeling in her right side, got over a bad stammer, and learned to walk almost normally.
"I am fully convinced that the improvements came from that operation," says Ms. Elam, now 67
